Recent Updates
Recently added Catalysts

RGX-202

Phase 2/3

Duchenne Muscular Dystrophy | Gene Therapies | Neurology |REGENXBIO Inc.|Trials Updated: Jul 21, 2026

RGX-202 development status

Highest phase Phase 2/3
Registered trials 2 across 1 sponsor since Jan 2023

RGX-202 target and mechanism

Molecular targetdystrophin
Target classProtein
ModalityGene Therapies

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDDMC
Total Trials1
Total Enrollment65

FDA Designations

FAST_TRACKORPHAN_DRUGRARE_PEDIATRIC_DISEASE

RGX-202 clinical trials

RGX-202 · 1 trial · 1 indication

Phase 2/3 1
NCT05693142AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)Duchenne Muscular Dystrophy
ACTIVE NOT_RECRUITING65 Analytics
PHASE2/PHASE3ACTIVE NOT_RECRUITING
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular DystrophyUnlock trial analytics

Study Endpoints

Primary Endpoints

Part 1 Safety measured by incidence of Adverse Events and Serious Adverse Events
52 weeks

Evaluate incidences of AEs and SAEs

Part 2 and 3 Pharmacodynamic
12 weeks

Proportion of participants whose RGX-202 microdystrophin protein expression determined in their muscle biopsy is ≥ 10% relative to dystrophin level in non-DMD participants

Secondary Endpoints

Time to Stand (TTSTAND)
52 Weeks (Part 1); 52 and 104 Weeks (Part 2 &3)
Time to Walk/Run 10 meters (TTWR)
52 Weeks (Part 1) and 104 Weeks (Part 2 &3)
Time to Climb 4 Stairs (TTCLIMB)
52 Weeks (Part 1); 52 and 104 Weeks (Part 2 &3)
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part 1: Cohort 1 and 1b (enrollment complete): RGX-202 Dose 1EXPERIMENTALA single IV infusion of RGX-202 at a dose of 1×10\^14 GC/kg body weight
Part 1: Cohort 2, 2c;, and Part 2; and Part 3 (enrollment complete for all): RGX-202 Dose 2EXPERIMENTALA single IV infusion of RGX-202 at a dose of 2x10\^14 GC/kg body weight (or a fixed dose of 1.00×10\^16 GC \[150 mL\] for participants weighing \> 50 kg)

Interventions

NameTypeDescription
RGX-202GENETICRGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin
Unlock Study Design Details

Eligibility Criteria

Age Range1 Year to N/A
SexMALE
Healthy VolunteersNo
Study Sites23

Part 1 - Key Inclusion Criteria: * The participant's legal guardian(s) is (are) willing and able to provide written, signed informed consent prior to any study-related procedures; and, where applicable, the minor participant has provided written or verbal assent according to local requirements. * I...

Countries:United StatesCanada
Unlock Eligibility Criteria

Frequently asked questions about RGX-202

What is RGX-202 used for?

RGX-202 is an investigational gene therapy being developed for Duchenne Muscular Dystrophy (DMD), a rare genetic muscle-wasting disease. It is designed as a one-time treatment for patients with DMD and is currently in Phase 2 clinical development. It has not been approved by the FDA.

How does RGX-202 work?

RGX-202 targets dystrophin, the protein missing or defective in Duchenne Muscular Dystrophy. It is a gene therapy designed to deliver a functional version of the dystrophin gene to muscle cells, aiming to restore dystrophin production. Dystrophin is essential for muscle fiber stability and function.

Who is developing RGX-202?

RGX-202 is being developed by REGENXBIO Inc., a clinical-stage biotechnology company. REGENXBIO trades on the Nasdaq under the ticker symbol RGNX. The company is the sponsor of the ongoing clinical trial for RGX-202 in Duchenne Muscular Dystrophy.

What phase is RGX-202 in?

RGX-202 is in Phase 2 clinical development. It is an investigational gene therapy and has not been approved by the FDA for any indication. The Phase 2 trial is currently active but not recruiting participants.

What clinical trials is RGX-202 in?

RGX-202 is being evaluated in a single Phase 2 clinical trial, NCT05693142, titled AFFINITY DUCHENNE. The trial is active but not recruiting and has an estimated enrollment of 65 male participants aged 1 year and older. It is conducted in the United States and Canada.

Does RGX-202 have FDA designations?

Yes, RGX-202 has received three FDA designations: Fast Track, Orphan Drug, and Rare Pediatric Disease. These designations are intended to support and expedite the development of therapies for serious rare diseases. RGX-202 remains investigational and has not been approved.